Latest News for: igg) antibodies

Edit

Breast Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 25 Mar 2025
In the meantime, HLX11 can also enhance the tumour-killing activity of immune cells via antibody-dependent cell cytotoxicity ... The therapeutic candidate is a full-length IgG bi-specific antibody that acts by targeting HER2 and HER3.
Edit

Game-changer in cancer treatment: New antibody therapy could replace chemotherapy to fight tumours

Hindustan Times 17 Mar 2025
As they act on different immune cells to IgG, IgE antibodies uniquely stimulate otherwise inactive immune cells in the 'microenvironment' surrounding the tumour to target the cancer cells directly.
Edit

Improving Immunity with a Next-Generation Whooping Cough Vaccine

The Scientist 17 Mar 2025
In this study, a single intranasal dose of BPZE1 with and without co-administration of tetanus, diphtheria, and acellular pertussis vaccine (Tdap, Boostrix®) induced mucosal antibody responses.
Edit

Scientists focus on a new antibody to fight treatment-resistant cancers

Suryaa 13 Mar 2025
As they act on different immune cells to IgG, IgE antibodies uniquely stimulate otherwise inactive immune cells in the ‘microenvironment’ surrounding the tumour to directly target the cancer cells.
Edit

Bullous Pemphigoid Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, ...

GetNews 12 Mar 2025
VYVGART (efgartigimod PH20 SC) developed by Argenx is an antibody fragment designed to reduce pathogenic immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor and blocking the IgG recycling process.
  • 1
×